These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 25016707)

  • 21. Characterization of inwardly rectifying K+ channel in human cardiac myocytes. Alterations in channel behavior in myocytes isolated from patients with idiopathic dilated cardiomyopathy.
    Koumi S; Backer CL; Arentzen CE
    Circulation; 1995 Jul; 92(2):164-74. PubMed ID: 7600647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum anti-p53 antibodies do not occur in patients with heart failure due to idiopathic dilated and ischemic cardiomyopathies.
    Izgi C; Cevik C; Ozdemir N; Kaymaz C; Ozkan M
    Eur J Heart Fail; 2005 Dec; 7(7):1095-8. PubMed ID: 16397925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myocardial Expression Analysis of Osteopontin and Its Splice Variants in Patients Affected by End-Stage Idiopathic or Ischemic Dilated Cardiomyopathy.
    Cabiati M; Svezia B; Matteucci M; Botta L; Pucci A; Rinaldi M; Caselli C; Lionetti V; Del Ry S
    PLoS One; 2016; 11(8):e0160110. PubMed ID: 27479215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determinants of high sensitivity troponin T concentration in chronic stable patients with heart failure: Ischemic heart failure versus non-ischemic dilated cardiomyopathy.
    Bakal RB; Hatipoglu S; Kahveci G; Omaygenc MO; Unkun T; Akgun T; Sahin M; Elveran A; Ozveren O; Ozdemir N
    Cardiol J; 2014; 21(1):67-75. PubMed ID: 23799554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The spatial pattern of coronary capillaries in patients with dilated, ischemic, or inflammatory cardiomyopathy.
    Karch R; Neumann F; Ullrich R; Neumüller J; Podesser BK; Neumann M; Schreiner W
    Cardiovasc Pathol; 2005; 14(3):135-44. PubMed ID: 15914298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes after atrioventricular node ablation and biventricular pacing in patients with refractory atrial fibrillation and heart failure: a comparison between non-ischaemic and ischaemic cardiomyopathy.
    Sohinki D; Ho J; Srinivasan N; Collins LJ; Obel OA
    Europace; 2014 Jun; 16(6):880-6. PubMed ID: 24525552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Nuclear changes and p62 expression in ischemic and dilated cardiomyopathy].
    Cortés R; Portolés M; Roselló-Lletí E; Martínez-Dolz L; Almenar L; Salvador A; Rivera M
    Rev Esp Cardiol; 2007 Dec; 60(12):1319-23. PubMed ID: 18082099
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of periodontal parameters between patients with ischemic and dilative cardiomyopathy.
    Ziebolz D; Binner C; Reuschel F; Eisner M; Wagner J; Kottmann T; Etz CD; Lehmann S; Garbade J; Schmalz G
    BMC Cardiovasc Disord; 2021 Jun; 21(1):304. PubMed ID: 34134635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of surgical ventricular reconstruction and mitral complex reconstruction on cardiac oxidative metabolism and efficiency in nonischemic and ischemic dilated cardiomyopathy.
    Sugiki T; Naya M; Manabe O; Wakasa S; Kubota S; Chiba S; Iwano H; Yamada S; Yoshinaga K; Tamaki N; Tsutsui H; Matsui Y
    JACC Cardiovasc Imaging; 2011 Jul; 4(7):762-70. PubMed ID: 21757167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Hypertrophic cardiomyopathy with dilatation of the left ventricle and congestive heart failure: comparison with postmyocarditis cardiomegaly and hypertensive heart failure].
    Kawanishi H; Yokota Y; Hayakawa M; Kaku K; Kumaki T; Matsumoto K; Fujitani K; Ito Y; Inoh T; Fukuzaki H
    J Cardiogr; 1983 Sep; 13(3):537-50. PubMed ID: 6235295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Machine learning-based classification and diagnosis of clinical cardiomyopathies.
    Alimadadi A; Manandhar I; Aryal S; Munroe PB; Joe B; Cheng X
    Physiol Genomics; 2020 Sep; 52(9):391-400. PubMed ID: 32744882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Measurements of baseline and follow-up concentrations of cardiac troponin-T and brain natriuretic peptide in patients with heart failure from various etiologies.
    Taniguchi R; Sato Y; Nishio Y; Kimura T; Kita T
    Heart Vessels; 2006 Nov; 21(6):344-9. PubMed ID: 17143708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elevation of plasma placental growth factor in the patients with ischemic cardiomyopathy.
    Nakamura T; Funayama H; Kubo N; Yasu T; Kawakami M; Momomura S; Ishikawa SE
    Int J Cardiol; 2009 Jan; 131(2):186-91. PubMed ID: 18192038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of serum tenascin-C levels on long-term outcome after acute myocardial infarction.
    Sato A; Hiroe M; Akiyama D; Hikita H; Nozato T; Hoshi T; Kimura T; Wang Z; Sakai S; Imanaka-Yoshida K; Yoshida T; Aonuma K
    J Card Fail; 2012 Jun; 18(6):480-6. PubMed ID: 22633306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prevalence of sleep-related breathing disorders in ischemic and non-ischemic heart failure].
    Oldenburg O; Lamp B; Töpfer V; Faber L; Teschler H; Horstkotte D
    Dtsch Med Wochenschr; 2007 Mar; 132(13):661-6. PubMed ID: 17377879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of tenascin-C levels in ventricular noncompaction/hypertrabeculation patients: a cross-sectional study.
    Erer HB; Guvenc TS; Kemik AS; Yilmaz H; Kul S; Altay S; Oz D; Zeren G; Ekmekci A; Zencirci AE; Sayar N; Eren M
    Echocardiography; 2014 Feb; 31(2):203-8. PubMed ID: 23895622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of troponin I-autoantibodies in chronic dilated and ischemic cardiomyopathy.
    Doesch AO; Mueller S; Nelles M; Konstandin M; Celik S; Frankenstein L; Goeser S; Kaya Z; Koch A; Zugck C; Katus HA
    Basic Res Cardiol; 2011 Jan; 106(1):25-35. PubMed ID: 20957484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure.
    Jirak P; Fejzic D; Paar V; Wernly B; Pistulli R; Rohm I; Jung C; Hoppe UC; Schulze PC; Lichtenauer M; Yilmaz A; Kretzschmar D
    Acta Pharmacol Sin; 2018 Jul; 39(7):1189-1196. PubMed ID: 29239349
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significance of myocardial tenascin-C expression in left ventricular remodelling and long-term outcome in patients with dilated cardiomyopathy.
    Yokokawa T; Sugano Y; Nakayama T; Nagai T; Matsuyama TA; Ohta-Ogo K; Ikeda Y; Ishibashi-Ueda H; Nakatani T; Yasuda S; Takeishi Y; Ogawa H; Anzai T
    Eur J Heart Fail; 2016 Apr; 18(4):375-85. PubMed ID: 26763891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can serum tenascin-C be used as a marker of inflammation in patients with dilated cardiomyopathy?
    Kotby AA; Abdel Aziz MM; El Guindy WM; Moneer AN
    Int J Pediatr; 2013; 2013():608563. PubMed ID: 24106506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.